NSRXNYSEPharmaceutical PreparationsUS GAAP · USD

Nasus Pharma Ltd

Nasus Pharma Ltd is a clinical-stage pharmaceutical company focused on developing innovative intranasal drug products. The company is based in Tel Aviv, Israel and is organized around a proprietary intranasal technology platform and a pipeline of powder-based therapeutic candidates.

Kysy yhtiöstä
Liikevaihto1 235milj. USD
Liikevoitto (EBIT)−4,9milj. USD
−354,9 %v/v
EBIT-marginaali−0,4%
Nettotulos−5,9milj. USD
−282,2 %v/v
Vapaa kassavirta−4,9milj. USD

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2023–2025

−25002505007501 0001 250milj. USD2023: EBIT −1,1 milj. USD20232024: EBIT −1,1 milj. USD20242025: 1 235 milj. USD2025: EBIT −4,9 milj. USD20251 235−4,9
LiikevaihtoLiikevoitto (EBIT)
Kysy Clarifolta: Nasus Pharma Ltd

Liiketoiminta

Osuus liikevaihdosta
NS0020 %

A powder-based intranasal epinephrine product candidate being developed for allergic reaction treatment.

Intranasal platform programs0 %

Additional proprietary intranasal powder-based programs targeting other therapeutic areas.

Clinical development100 %

Preclinical, clinical, and regulatory work required to advance product candidates toward approval.

Asiakkaat

Nasus Pharma does not sell commercial products broadly; its direct counterparties are primarily investors, clinical research vendors, and regulatory stakeholders. The eventual customers for its products would be patients, physicians, and healthcare providers that use intranasal treatments for conditions where rapid administration is clinically valuable.

Capital providers

Investors and financing counterparties that fund ongoing development and platform expansion.

Clinical development partners

CROs, laboratories, and consultants that support trials, manufacturing, and regulatory work.

Regulators

Agencies that review clinical data and NDA submissions for NS002 and related programs.

Future healthcare customers

Patients, physicians, and healthcare systems that could use approved intranasal products.

Strategia

Nasus Pharma's strategy is to advance NS002 toward pivotal study and NDA submission while broadening its intranasal platform into additional therapeutic areas. The company is trying to build a differentiated product family around powder-based intranasal administration, where faster or more convenient delivery could create clinical value versus existing options.

Advance NS002 into pivotal studyLyhyt aikaväli

Clinical proof and regulatory progress are the key value drivers for a single-asset biotech platform.

Expand the intranasal pipelineKeskipitkä aikaväli

A broader pipeline can reduce dependence on one candidate and increase platform optionality.

Strengthen capital runwayLyhyt aikaväli

Clinical-stage development requires sustained funding before any product revenue exists.

Maantiede

The company is incorporated as a foreign private issuer with principal executive offices in Tel Aviv, Israel and trades in the United States on the NYSE. Its development work is centered around its Israeli base, while its capital markets access and future commercialization pathway are tied to the U.S. pharmaceutical market.

Riskit

Nasus Pharma faces the typical risks of a clinical-stage pharmaceutical company: trial failure, regulatory delay, and the possibility that the product profile does not translate into approval or adoption. As a single-platform developer, it is also exposed to financing risk, concentration in a limited number of candidates, and execution risk across manufacturing, clinical operations, and NDA preparation.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Clinical failure of NS0021Regulatory delay or rejection4Financing dependence2Pipeline concentration3
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Clinical failure of NS002Vaikutus: KriittinenTodennäköisyys: Kohtalainen

    The business case depends on positive pivotal data and eventual approval for its lead candidate.

    Kohdistuu: Lead asset

  2. Financing dependenceVaikutus: KorkeaTodennäköisyys: Korkea

    Clinical-stage operations require recurring capital before any meaningful product sales exist.

    Kohdistuu: Operating runway

  3. Pipeline concentrationVaikutus: KorkeaTodennäköisyys: Korkea

    A narrow portfolio means setbacks in one program can disproportionately affect enterprise value.

    Kohdistuu: Product pipeline

  4. Regulatory delay or rejectionVaikutus: KorkeaTodennäköisyys: Kohtalainen

    FDA review outcomes can materially affect timing, cost, and the chance of market entry.

    Kohdistuu: NDA submission and approval

Kysy Clarifolta: Nasus Pharma Ltd

Kirjanpito

Harkinnanvaraiset erät
Discontinued operations

Taffix is presented separately, which affects comparability of operating results across periods.

Vaikutus: Changes reported loss and segment presentation

Share-based compensation

Equity awards are a meaningful expense in a development-stage company and increase non-cash costs.

Vaikutus: Raises reported operating expenses

Financing costs and warrants

Private placements can create issuance costs and warrant valuation effects that influence net results.

Vaikutus: Affects equity, expenses, and dilution

R&D expense timing

Clinical and regulatory spending is expensed as incurred, making results sensitive to trial timing.

Vaikutus: Creates period-to-period volatility

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

ARS Pharmaceuticals, Inc.

SPRY · Pharmaceutical Preparations

Kairos Pharma, LTD.

KAPA · Pharmaceutical Preparations

ENvue Medical, Inc.

FEED · Orthopedic, Prosthetic & Surgical Appliances & Supplies

NeuroSense Therapeutics Ltd.

NRSNW · Pharmaceutical Preparations

Can-Fite BioPharma Ltd.

CANF · Pharmaceutical Preparations

Semnur Pharmaceuticals, Inc.

SMNR · Pharmaceutical Preparations

Päivitetty: 28.9.2026

Nasus Pharma Ltd (NYSE) – Pharmaceutical Preparations | Analyysi – Clarifo